Marinomed Biotech AG Logo

Marinomed Biotech AG

Develops virus-blocking products & immunology therapies via proprietary technology platforms.

MARI | VI

Overview

Corporate Details

ISIN(s):
ATMARINOMED6
LEI:
529900GN3B1EN80XF405
Country:
Austria
Address:
Hovengasse 25, 2100 Korneuburg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Marinomed Biotech AG is a science-based biopharmaceutical company that develops innovative therapies for diseases in virology and immunology. The company leverages two proprietary technology platforms: Carragelose®, a virus-blocking compound used in globally marketed nasal sprays and lozenges, and Marinosolv®, a technology platform that enhances the solubility of poorly soluble compounds to develop new treatments for various immunological conditions. Marinomed's business model encompasses in-house development of medicinal products and medical devices, as well as strategic partnerships to commercialize its pipeline and technologies. The company focuses on addressing conditions with limited or no effective treatment options, particularly in respiratory and autoreactive immune disorders.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 10:01
Declaration of Voting Results & Voting Rights Announcements
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 Börs…
English 16.5 KB
2025-10-31 10:01
Declaration of Voting Results & Voting Rights Announcements
EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 13…
German 17.0 KB
2025-10-31 10:00
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 135, Section 1 BorseG with the objective of Europe…
English 3.6 KB
2025-10-06 14:58
Regulatory News Service
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Mari…
English 34.6 KB
2025-10-06 14:58
M&A Activity
EQS-Adhoc: Marinomed Biotech AG startet Prüfung strategischer Optionen für die …
German 36.4 KB
2025-10-06 14:56
Regulatory News Service
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv plat…
English 11.1 KB
2025-09-17 13:48
Earnings Release
Marinomed Biotech AG announces results for the first half year of 2025
English 10.6 KB
2025-09-17 13:42
Interim Report
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
English 3.4 MB
2025-09-17 13:42
Interim Report
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines F…
German 3.5 MB
2025-09-16 15:24
Share Issue/Capital Change
EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory s…
English 31.7 KB
2025-09-16 15:24
Share Issue/Capital Change
EQS-Adhoc: Marinomed Biotech AG beschließt Kapitalerhöhung unter Bezugsrechtsau…
German 33.7 KB
2025-09-16 15:22
Share Issue/Capital Change
Marinomed Biotech AG resolves capital increase excluding statutory subscription…
English 8.0 KB
2025-09-02 09:18
Pre-Annual General Meeting Information
EQS-AGM: Marinomed Biotech AG: Convening of an Extraordinary General Meeting fo…
English 51.6 KB
2025-09-02 09:17
Pre-Annual General Meeting Information
EQS-HV: Marinomed Biotech AG: Einberufung einer außerordentlichen Hauptversamml…
German 50.1 KB
2025-09-02 09:16
Pre-Annual General Meeting Information
Marinomed Biotech AG: Convening of an Extraordinary General Meeting for Tuesday…
English 21.9 KB

Automate Your Workflow. Get a real-time feed of all Marinomed Biotech AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Marinomed Biotech AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Marinomed Biotech AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany NN6
NANOVIRICIDES, INC. Logo
Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.
United States of America NNVC
Nasus Pharma Ltd Logo
Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.
United States of America NSRX
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain NAT
Natera, Inc. Logo
Provides non-invasive cfDNA tests for oncology, women's health, and organ health.
United States of America NTRA
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea 168330
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom NATUR
NEKTAR THERAPEUTICS Logo
Biopharma developing innovative medicines for autoimmune and inflammatory conditions.
United States of America NKTR
NEOGEN CORP Logo
Provides diagnostic tests and genomics services for food, animal, and agricultural safety.
United States of America NEOG
NEOGENOMICS INC Logo
Provides precision oncology testing for cancer diagnostics, therapy guidance, and research.
United States of America NEO

Talk to a Data Expert

Have a question? We'll get back to you promptly.